Publication:
Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting?

Simple item page
dc.contributor.authorBesiroglu, Mehmet
dc.contributor.authorDemir, Tarik
dc.contributor.authorShbair, Abdallah T M
dc.contributor.authorYasin, Ayse Irem
dc.contributor.authorTopcu, Atakan
dc.contributor.authorTurk, HACI MEHMET
dc.contributor.institutionauthorTÜRK, HACI MEHMET
dc.date.accessioned2021-08-03T20:59:13Z
dc.date.available2021-08-03T20:59:13Z
dc.date.issued2021-08-01T00:00:00Z
dc.identifier.citationBesiroglu M., Demir T., Shbair A. T. M. , Yasin A. I. , Topcu A., Turk H. M. , -Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting?-, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, cilt.31, ss.932-936, 2021
dc.identifier.doi10.29271/jcpsp.2021.08.932
dc.identifier.pubmed34320710
dc.identifier.urihttp://hdl.handle.net/20.500.12645/29106
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleIs the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting?
dc.typeArticle
dspace.entity.typePublication
local.avesis.id3a66bed1-4c21-430e-92d8-362488afc22e
local.indexed.atPubMed
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
local.publication.isinternational1
relation.isAuthorOfPublication1b3a1540-7e57-405d-8a9d-f926d17dcc29
relation.isAuthorOfPublication.latestForDiscovery1b3a1540-7e57-405d-8a9d-f926d17dcc29
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c

Files

Collections

Yayınlar - Eserler